Collaborative Research and Development Agreements (Tables)

6 Months Ended

Jun. 30, 2014

Agreement With Gsk

Summary of Revenue Recognized under Various Agreements

The following table summarizes the revenues recognized under our agreement with GSK, included as collaboration revenue in our statement of operations (in thousands):

	Three Months Ended				Six Months Ended
	June 30,				June 30,
	2014		2013		2014		2013
Initial payment	$	631	$	357	$	1,262	$	714
Total	$	631	$	357	$	1,262	$	714

Astra Zeneca

Summary of Revenue Recognized under Various Agreements

The following table summarizes the revenues earned under our agreement with AstraZeneca, included as collaboration revenue in our statement of operations (in thousands):

	Three Months Ended				Six Months Ended
	June 30,				June 30,
	2014		2013		2014		2013
Initial payment	$	180	$	180	$	360	$	360
Subsequent payment		675		-		1,350		-
Performance of research activities		545		819		1,432		1,165
Total	$	1,400	$	999	$	3,142	$	1,525

National Institutes of Health

Summary of Revenue Recognized under Various Agreements

The following table summarizes the revenues recognized under the various arrangements with the NIH and NIAID, included as grant revenue in our statement of operations (in thousands):

	Three Months Ended				Six Months Ended
	June 30,				June 30,
	2014		2013		2014		2013
NIAID contracts	$	965	$	1,062	$	1,839	$	1,660
All other NIH contracts		42		333		293		495
Total grant revenue	$	1,007	$	1,395	$	2,132	$	2,155